Transcatheter Aortic Valve Implantation with ACURATE neo: Results from the PROGRESS PVL Registry

Figure 3

Improvement in aortic regurgitation. (a) The primary endpoint of PROGRESS PVL was the rate of total aortic regurgitation (AR), assessed by an independent echocardiography laboratory at discharge/7 days, 30 days, and 12 months in patients treated with ACURATE neo. Paravalvular leak (PVL) was very similar to total AR at all time points. (b, c) Paired analyses performed in patients with data available at both discharge and 12 months (N = 209) demonstrated significant overall improvement in PVL (; Bhapkar’s test for marginal homogeneity), with a greater proportion of patients showing interindividual improvement in PVL compared with worsening PVL. All echocardiographic data were assessed by a core laboratory.

(a)

(b)

(c)